This year’s PE50 shows an industry whose growth has slowed to a crawl in the face of patent expirations, aggressive payers, and a tough environment for approvals. The 50 this year sold $610 billion in human prescription pharmaceuticals, up just 2.8 percent from last year’s $593 billion. The top 10 grew even more slowly—by just 2.6 percent—and accounted for 59 percent of the 50’s total sales, just like last year. Find out who’s in, who’s out, and who came out on top in our annual, must-read ranking of the world's top pharma companies… Sponsored By: DSM is a pharmaceutical outsourcing manufacturing partner committed to meet market demand globally providing quality, regulatory excellence and innovations for sustainability.